Quidel (QDEL) Gets CE Mark for Molecular RSV + hMPV Assay
Tweet
Share
E-mailGet Alerts QDEL Hot Sheet
Join SI Premium – FREE
Quidel Corporation (Nasdaq: QDEL), has received the CE Mark for the Quidel Molecular" RSV + hMPV assay for the detection of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
The CE Mark for Quidel's molecular RSV + hMPV assay clears the way for the launch of another infectious disease molecular test offering in Europe. The assay distinguishes between RSV and hMPV, two different viruses that cause respiratory infections with very similar symptoms.
The CE Mark for Quidel's molecular RSV + hMPV assay clears the way for the launch of another infectious disease molecular test offering in Europe. The assay distinguishes between RSV and hMPV, two different viruses that cause respiratory infections with very similar symptoms.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Kimbell Royalty closes $221.2M mineral rights acquisition
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
